New rules will force EU medtech notified bodies to up their game
This article was originally published in SRA
Executive Summary
The European Commission has adopted two measures that it says are aimed at strengthening the safety of medical devices and restoring consumer confidence in the industry following the PIP breast implant affair1. The measures clarify the criteria to be met by notified bodies and the tasks these bodies have to undertake when they perform audits and assessments in the medical devices and in vitro diagnostics sector.
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.